Protocol Ledger

NCT05289037 · Phase II · COMPLETED

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Interventional Phase II clinical trial protocol NCT05289037 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-30 Enrollment: 1,270 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05289037
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,270 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05289037
Protocol FieldVerified Registry Value
NCT IdentifierNCT05289037
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,270 participants (ACTUAL)
Registered Start Date2022-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05289037
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI